Skip to content
Research Article Open access CC BY 4.0

D-Penicillamine in the Neonatal Period: Case Reports

Lajos Lakatos, György Balla, István Pataki, Zsuzsanna Vekerdy-Nagy, György Oroszlán

International Journal of Medical and Pharmaceutical Case Reports · pp. 59–63 · Published 2 May 2015

10.9734/IJMPCR/2015/17239

Abstract

D-Penicillamine (DPA) was first recognized as a potential benefit for neonatal hyperbilirubinemia (NHBI). During this time there was a remarkedly low incidence of retinopathy of prematurity (ROP) in the infants treated with DPA. Later, our studies were replicated in other institutes in Hungary, Poland, U.S.A., India and Mexico. It is important to note that there was no intolerance or short- or long-term toxicity of the medication, in spite of the fact that in the newborn period DPA was used 10-20 times higher doses (3 x 100 mg/kg bw./day IV for 3-7 days in the neonatal jaundice + once daily 50 mg/kg bw. IV until the end of the second week of life to prevent ROP) than those in adult. There were some very impressive cases in our practice in neonatology which deserved to be shown individually.

D-Penicillamine neonatal hyperbilirubinemia retinopathy of prematurity.

Cited by 4

4 citations reported by external sources — individual citing-article records aren't available to list yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

4

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.